Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) Stock Competitors & Peer Comparison
See ALNY's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for ALNY and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ALNY | $240.08 | +1.72% | 32.1B | 43.26 | $5.55 | N/A |
| VRTX | $552.85 | +0.96% | 140.3B | 29.05 | $19.03 | N/A |
| REGN | $833.56 | +0.61% | 85.9B | 18.27 | $45.63 | +0.45% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $1,019.49 | +0.83% | 63.4B | 92.01 | $11.08 | N/A |
| MRNA | $158.83 | +14.36% | 63B | -19.49 | -$8.15 | N/A |
| RVMDW | $11.98 | -0.42% | 47.4B | -1.67 | -$7.21 | N/A |
| RVMD | $211.38 | -0.09% | 44.9B | -23.97 | -$8.82 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ONC | $376.37 | +1.18% | 40.2B | 66.26 | $5.68 | N/A |
Stock Comparison
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
ALNY vs VRTX Comparison August 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 32.1B. In comparison, VRTX has a market cap of 140.3B. Regarding current trading prices, ALNY is priced at $240.08 on the NASDAQ, while VRTX trades at $552.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 43.26, whereas VRTX's P/E ratio is 29.05. In terms of profitability, ALNY's ROE is +0.94%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, ALNY is more volatile compared to VRTX. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check VRTX's competition here
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
ALNY vs REGN Comparison August 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 32.1B. In comparison, REGN has a market cap of 85.9B. Regarding current trading prices, ALNY is priced at $240.08 on the NASDAQ, while REGN trades at $833.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 43.26, whereas REGN's P/E ratio is 18.27. In terms of profitability, ALNY's ROE is +0.94%, compared to REGN's ROE of +0.14%. Regarding short-term risk, ALNY is more volatile compared to REGN. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check REGN's competition here
Verona Pharma plc (NASDAQ: VRNA)
ALNY vs VRNA Comparison August 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 32.1B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, ALNY is priced at $240.08 on the NASDAQ, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 43.26, whereas VRNA's P/E ratio is -102.80. In terms of profitability, ALNY's ROE is +0.94%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, ALNY is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check VRNA's competition here
argenx SE (NASDAQ: ARGX)
ALNY vs ARGX Comparison August 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 32.1B. In comparison, ARGX has a market cap of 63.4B. Regarding current trading prices, ALNY is priced at $240.08 on the NASDAQ, while ARGX trades at $1,019.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 43.26, whereas ARGX's P/E ratio is 92.01. In terms of profitability, ALNY's ROE is +0.94%, compared to ARGX's ROE of +0.32%. Regarding short-term risk, ALNY is more volatile compared to ARGX. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check ARGX's competition here
Moderna, Inc. (NASDAQ: MRNA)
ALNY vs MRNA Comparison August 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 32.1B. In comparison, MRNA has a market cap of 63B. Regarding current trading prices, ALNY is priced at $240.08 on the NASDAQ, while MRNA trades at $158.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 43.26, whereas MRNA's P/E ratio is -19.49. In terms of profitability, ALNY's ROE is +0.94%, compared to MRNA's ROE of -0.39%. Regarding short-term risk, ALNY is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check MRNA's competition here
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW)
ALNY vs RVMDW Comparison August 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 32.1B. In comparison, RVMDW has a market cap of 47.4B. Regarding current trading prices, ALNY is priced at $240.08 on the NASDAQ, while RVMDW trades at $11.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 43.26, whereas RVMDW's P/E ratio is -1.67. In terms of profitability, ALNY's ROE is +0.94%, compared to RVMDW's ROE of -0.96%. Regarding short-term risk, ALNY is less volatile compared to RVMDW. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check RVMDW's competition here
Revolution Medicines, Inc. (NASDAQ: RVMD)
ALNY vs RVMD Comparison August 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 32.1B. In comparison, RVMD has a market cap of 44.9B. Regarding current trading prices, ALNY is priced at $240.08 on the NASDAQ, while RVMD trades at $211.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 43.26, whereas RVMD's P/E ratio is -23.97. In terms of profitability, ALNY's ROE is +0.94%, compared to RVMD's ROE of -0.96%. Regarding short-term risk, ALNY is less volatile compared to RVMD. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check RVMD's competition here
Seagen Inc. (NASDAQ: SGEN)
ALNY vs SGEN Comparison August 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 32.1B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, ALNY is priced at $240.08 on the NASDAQ, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 43.26, whereas SGEN's P/E ratio is -57.19. In terms of profitability, ALNY's ROE is +0.94%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, ALNY is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check SGEN's competition here
BeOne Medicines AG (NASDAQ: ONC)
ALNY vs ONC Comparison August 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 32.1B. In comparison, ONC has a market cap of 40.2B. Regarding current trading prices, ALNY is priced at $240.08 on the NASDAQ, while ONC trades at $376.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 43.26, whereas ONC's P/E ratio is 66.26. In terms of profitability, ALNY's ROE is +0.94%, compared to ONC's ROE of +0.14%. Regarding short-term risk, ALNY is less volatile compared to ONC. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check ONC's competition here
BioNTech SE (NASDAQ: BNTX)
ALNY vs BNTX Comparison August 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 32.1B. In comparison, BNTX has a market cap of 28.6B. Regarding current trading prices, ALNY is priced at $240.08 on the NASDAQ, while BNTX trades at $114.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 43.26, whereas BNTX's P/E ratio is -14.79. In terms of profitability, ALNY's ROE is +0.94%, compared to BNTX's ROE of -0.09%. Regarding short-term risk, ALNY is less volatile compared to BNTX. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check BNTX's competition here
Insmed Incorporated (NASDAQ: INSM)
ALNY vs INSM Comparison August 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 32.1B. In comparison, INSM has a market cap of 26.9B. Regarding current trading prices, ALNY is priced at $240.08 on the NASDAQ, while INSM trades at $123.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 43.26, whereas INSM's P/E ratio is -30.14. In terms of profitability, ALNY's ROE is +0.94%, compared to INSM's ROE of -1.11%. Regarding short-term risk, ALNY is less volatile compared to INSM. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check INSM's competition here
Roivant Sciences Ltd. (NASDAQ: ROIV)
ALNY vs ROIV Comparison August 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 32.1B. In comparison, ROIV has a market cap of 26.3B. Regarding current trading prices, ALNY is priced at $240.08 on the NASDAQ, while ROIV trades at $36.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 43.26, whereas ROIV's P/E ratio is -34.70. In terms of profitability, ALNY's ROE is +0.94%, compared to ROIV's ROE of -0.06%. Regarding short-term risk, ALNY is less volatile compared to ROIV. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check ROIV's competition here
Incyte Corporation (NASDAQ: INCY)
ALNY vs INCY Comparison August 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 32.1B. In comparison, INCY has a market cap of 26.3B. Regarding current trading prices, ALNY is priced at $240.08 on the NASDAQ, while INCY trades at $129.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 43.26, whereas INCY's P/E ratio is 17.44. In terms of profitability, ALNY's ROE is +0.94%, compared to INCY's ROE of +0.30%. Regarding short-term risk, ALNY is less volatile compared to INCY. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check INCY's competition here
United Therapeutics Corporation (NASDAQ: UTHR)
ALNY vs UTHR Comparison August 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 32.1B. In comparison, UTHR has a market cap of 22B. Regarding current trading prices, ALNY is priced at $240.08 on the NASDAQ, while UTHR trades at $518.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 43.26, whereas UTHR's P/E ratio is 18.55. In terms of profitability, ALNY's ROE is +0.94%, compared to UTHR's ROE of +0.20%. Regarding short-term risk, ALNY is more volatile compared to UTHR. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check UTHR's competition here
Genmab A/S (NASDAQ: GMAB)
ALNY vs GMAB Comparison August 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 32.1B. In comparison, GMAB has a market cap of 21.1B. Regarding current trading prices, ALNY is priced at $240.08 on the NASDAQ, while GMAB trades at $34.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 43.26, whereas GMAB's P/E ratio is 25.89. In terms of profitability, ALNY's ROE is +0.94%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, ALNY is more volatile compared to GMAB. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check GMAB's competition here
BeiGene, Ltd. (NASDAQ: BGNE)
ALNY vs BGNE Comparison August 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 32.1B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, ALNY is priced at $240.08 on the NASDAQ, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 43.26, whereas BGNE's P/E ratio is -22.55. In terms of profitability, ALNY's ROE is +0.94%, compared to BGNE's ROE of +0.14%. Regarding short-term risk, ALNY is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check BGNE's competition here
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT)
ALNY vs DNA-WT Comparison August 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 32.1B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, ALNY is priced at $240.08 on the NASDAQ, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 43.26, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, ALNY's ROE is +0.94%, compared to DNA-WT's ROE of -0.60%. Regarding short-term risk, ALNY is less volatile compared to DNA-WT. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check DNA-WT's competition here
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
ALNY vs JAZZ Comparison August 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 32.1B. In comparison, JAZZ has a market cap of 16.3B. Regarding current trading prices, ALNY is priced at $240.08 on the NASDAQ, while JAZZ trades at $260.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 43.26, whereas JAZZ's P/E ratio is 9.70. In terms of profitability, ALNY's ROE is +0.94%, compared to JAZZ's ROE of +0.21%. Regarding short-term risk, ALNY is less volatile compared to JAZZ. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check JAZZ's competition here
BridgeBio Pharma, Inc. (NASDAQ: BBIO)
ALNY vs BBIO Comparison August 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 32.1B. In comparison, BBIO has a market cap of 15.7B. Regarding current trading prices, ALNY is priced at $240.08 on the NASDAQ, while BBIO trades at $80.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 43.26, whereas BBIO's P/E ratio is -21.50. In terms of profitability, ALNY's ROE is +0.94%, compared to BBIO's ROE of +0.32%. Regarding short-term risk, ALNY is less volatile compared to BBIO. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check BBIO's competition here
Ascendis Pharma A/S (NASDAQ: ASND)
ALNY vs ASND Comparison August 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 32.1B. In comparison, ASND has a market cap of 15.7B. Regarding current trading prices, ALNY is priced at $240.08 on the NASDAQ, while ASND trades at $252.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 43.26, whereas ASND's P/E ratio is -104.54. In terms of profitability, ALNY's ROE is +0.94%, compared to ASND's ROE of +1.90%. Regarding short-term risk, ALNY is more volatile compared to ASND. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check ASND's competition here
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
ALNY vs NBIX Comparison August 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 32.1B. In comparison, NBIX has a market cap of 15.4B. Regarding current trading prices, ALNY is priced at $240.08 on the NASDAQ, while NBIX trades at $153.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 43.26, whereas NBIX's P/E ratio is 22.16. In terms of profitability, ALNY's ROE is +0.94%, compared to NBIX's ROE of +0.21%. Regarding short-term risk, ALNY is less volatile compared to NBIX. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check NBIX's competition here
Exelixis, Inc. (NASDAQ: EXEL)
ALNY vs EXEL Comparison August 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 32.1B. In comparison, EXEL has a market cap of 14.3B. Regarding current trading prices, ALNY is priced at $240.08 on the NASDAQ, while EXEL trades at $56.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 43.26, whereas EXEL's P/E ratio is 16.21. In terms of profitability, ALNY's ROE is +0.94%, compared to EXEL's ROE of +0.42%. Regarding short-term risk, ALNY is less volatile compared to EXEL. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check EXEL's competition here
Halozyme Therapeutics, Inc. (NASDAQ: HALO)
ALNY vs HALO Comparison August 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 32.1B. In comparison, HALO has a market cap of 13B. Regarding current trading prices, ALNY is priced at $240.08 on the NASDAQ, while HALO trades at $109.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 43.26, whereas HALO's P/E ratio is 20.40. In terms of profitability, ALNY's ROE is +0.94%, compared to HALO's ROE of +1.81%. Regarding short-term risk, ALNY is more volatile compared to HALO. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check HALO's competition here
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
ALNY vs BMRN Comparison August 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 32.1B. In comparison, BMRN has a market cap of 12.8B. Regarding current trading prices, ALNY is priced at $240.08 on the NASDAQ, while BMRN trades at $66.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 43.26, whereas BMRN's P/E ratio is 31.79. In terms of profitability, ALNY's ROE is +0.94%, compared to BMRN's ROE of +0.01%. Regarding short-term risk, ALNY is more volatile compared to BMRN. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check BMRN's competition here
Karuna Therapeutics, Inc. (NASDAQ: KRTX)
ALNY vs KRTX Comparison August 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 32.1B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, ALNY is priced at $240.08 on the NASDAQ, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 43.26, whereas KRTX's P/E ratio is -28.09. In terms of profitability, ALNY's ROE is +0.94%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, ALNY is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check KRTX's competition here
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
ALNY vs ARWR Comparison August 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 32.1B. In comparison, ARWR has a market cap of 12.5B. Regarding current trading prices, ALNY is priced at $240.08 on the NASDAQ, while ARWR trades at $88.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 43.26, whereas ARWR's P/E ratio is -39.50. In terms of profitability, ALNY's ROE is +0.94%, compared to ARWR's ROE of -0.61%. Regarding short-term risk, ALNY is less volatile compared to ARWR. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check ARWR's competition here
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
ALNY vs MDGL Comparison August 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 32.1B. In comparison, MDGL has a market cap of 11.8B. Regarding current trading prices, ALNY is priced at $240.08 on the NASDAQ, while MDGL trades at $512.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 43.26, whereas MDGL's P/E ratio is -40.01. In terms of profitability, ALNY's ROE is +0.94%, compared to MDGL's ROE of -0.57%. Regarding short-term risk, ALNY is less volatile compared to MDGL. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check MDGL's competition here
Bio-Techne Corporation (NASDAQ: TECH)
ALNY vs TECH Comparison August 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 32.1B. In comparison, TECH has a market cap of 11.3B. Regarding current trading prices, ALNY is priced at $240.08 on the NASDAQ, while TECH trades at $72.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 43.26, whereas TECH's P/E ratio is 37.28. In terms of profitability, ALNY's ROE is +0.94%, compared to TECH's ROE of +0.09%. Regarding short-term risk, ALNY is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check TECH's competition here
Avidity Biosciences Inc (NASDAQ: RNAM)
ALNY vs RNAM Comparison August 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 32.1B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, ALNY is priced at $240.08 on the NASDAQ, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 43.26, whereas RNAM's P/E ratio is -17.39. In terms of profitability, ALNY's ROE is +0.94%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, ALNY is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check RNAM's competition here
Summit Therapeutics Inc. (NASDAQ: SMMT)
ALNY vs SMMT Comparison August 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 32.1B. In comparison, SMMT has a market cap of 10.7B. Regarding current trading prices, ALNY is priced at $240.08 on the NASDAQ, while SMMT trades at $13.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 43.26, whereas SMMT's P/E ratio is -11.93. In terms of profitability, ALNY's ROE is +0.94%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, ALNY is less volatile compared to SMMT. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check SMMT's competition here
Axsome Therapeutics, Inc. (NASDAQ: AXSM)
ALNY vs AXSM Comparison August 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 32.1B. In comparison, AXSM has a market cap of 10.6B. Regarding current trading prices, ALNY is priced at $240.08 on the NASDAQ, while AXSM trades at $205.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 43.26, whereas AXSM's P/E ratio is -53.65. In terms of profitability, ALNY's ROE is +0.94%, compared to AXSM's ROE of -2.56%. Regarding short-term risk, ALNY is less volatile compared to AXSM. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check AXSM's competition here
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
ALNY vs IONS Comparison August 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 32.1B. In comparison, IONS has a market cap of 10.6B. Regarding current trading prices, ALNY is priced at $240.08 on the NASDAQ, while IONS trades at $63.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 43.26, whereas IONS's P/E ratio is -36.96. In terms of profitability, ALNY's ROE is +0.94%, compared to IONS's ROE of -1.11%. Regarding short-term risk, ALNY is less volatile compared to IONS. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check IONS's competition here
Krystal Biotech, Inc. (NASDAQ: KRYS)
ALNY vs KRYS Comparison August 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 32.1B. In comparison, KRYS has a market cap of 10.5B. Regarding current trading prices, ALNY is priced at $240.08 on the NASDAQ, while KRYS trades at $356.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 43.26, whereas KRYS's P/E ratio is 44.64. In terms of profitability, ALNY's ROE is +0.94%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, ALNY is less volatile compared to KRYS. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check KRYS's competition here
Kymera Therapeutics, Inc. (NASDAQ: KYMR)
ALNY vs KYMR Comparison August 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 32.1B. In comparison, KYMR has a market cap of 10.4B. Regarding current trading prices, ALNY is priced at $240.08 on the NASDAQ, while KYMR trades at $126.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 43.26, whereas KYMR's P/E ratio is -39.57. In terms of profitability, ALNY's ROE is +0.94%, compared to KYMR's ROE of -0.22%. Regarding short-term risk, ALNY is less volatile compared to KYMR. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check KYMR's competition here
Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
ALNY vs PRAX Comparison August 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 32.1B. In comparison, PRAX has a market cap of 10.3B. Regarding current trading prices, ALNY is priced at $240.08 on the NASDAQ, while PRAX trades at $368.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 43.26, whereas PRAX's P/E ratio is -28.46. In terms of profitability, ALNY's ROE is +0.94%, compared to PRAX's ROE of -0.34%. Regarding short-term risk, ALNY is less volatile compared to PRAX. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check PRAX's competition here
Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
ALNY vs PTGX Comparison August 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 32.1B. In comparison, PTGX has a market cap of 9.7B. Regarding current trading prices, ALNY is priced at $240.08 on the NASDAQ, while PTGX trades at $150.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 43.26, whereas PTGX's P/E ratio is 146.20. In terms of profitability, ALNY's ROE is +0.94%, compared to PTGX's ROE of +0.12%. Regarding short-term risk, ALNY is less volatile compared to PTGX. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check PTGX's competition here
Cytokinetics, Incorporated (NASDAQ: CYTK)
ALNY vs CYTK Comparison August 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 32.1B. In comparison, CYTK has a market cap of 9.6B. Regarding current trading prices, ALNY is priced at $240.08 on the NASDAQ, while CYTK trades at $77.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 43.26, whereas CYTK's P/E ratio is -10.73. In terms of profitability, ALNY's ROE is +0.94%, compared to CYTK's ROE of +1.64%. Regarding short-term risk, ALNY is more volatile compared to CYTK. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check CYTK's competition here
Prometheus Biosciences, Inc. (NASDAQ: RXDX)
ALNY vs RXDX Comparison August 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 32.1B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, ALNY is priced at $240.08 on the NASDAQ, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 43.26, whereas RXDX's P/E ratio is -56.47. In terms of profitability, ALNY's ROE is +0.94%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, ALNY is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check RXDX's competition here
Spyre Therapeutics, Inc. (NASDAQ: SYRE)
ALNY vs SYRE Comparison August 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 32.1B. In comparison, SYRE has a market cap of 9.3B. Regarding current trading prices, ALNY is priced at $240.08 on the NASDAQ, while SYRE trades at $107.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 43.26, whereas SYRE's P/E ratio is -55.06. In terms of profitability, ALNY's ROE is +0.94%, compared to SYRE's ROE of -0.24%. Regarding short-term risk, ALNY is less volatile compared to SYRE. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check SYRE's competition here
Nuvalent, Inc. (NASDAQ: NUVL)
ALNY vs NUVL Comparison August 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 32.1B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, ALNY is priced at $240.08 on the NASDAQ, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 43.26, whereas NUVL's P/E ratio is -21.79. In terms of profitability, ALNY's ROE is +0.94%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, ALNY is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check NUVL's competition here
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
ALNY vs CRNX Comparison August 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 32.1B. In comparison, CRNX has a market cap of 9B. Regarding current trading prices, ALNY is priced at $240.08 on the NASDAQ, while CRNX trades at $84.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 43.26, whereas CRNX's P/E ratio is -16.84. In terms of profitability, ALNY's ROE is +0.94%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, ALNY is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check CRNX's competition here
Immunovant, Inc. (NASDAQ: IMVT)
ALNY vs IMVT Comparison August 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 32.1B. In comparison, IMVT has a market cap of 9B. Regarding current trading prices, ALNY is priced at $240.08 on the NASDAQ, while IMVT trades at $43.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 43.26, whereas IMVT's P/E ratio is -15.43. In terms of profitability, ALNY's ROE is +0.94%, compared to IMVT's ROE of -0.70%. Regarding short-term risk, ALNY is less volatile compared to IMVT. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check IMVT's competition here
Vaxcyte, Inc. (NASDAQ: PCVX)
ALNY vs PCVX Comparison August 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 32.1B. In comparison, PCVX has a market cap of 8.8B. Regarding current trading prices, ALNY is priced at $240.08 on the NASDAQ, while PCVX trades at $61.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 43.26, whereas PCVX's P/E ratio is -8.01. In terms of profitability, ALNY's ROE is +0.94%, compared to PCVX's ROE of -0.38%. Regarding short-term risk, ALNY is less volatile compared to PCVX. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check PCVX's competition here
ImmunoGen, Inc. (NASDAQ: IMGN)
ALNY vs IMGN Comparison August 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 32.1B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, ALNY is priced at $240.08 on the NASDAQ, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 43.26, whereas IMGN's P/E ratio is -111.55. In terms of profitability, ALNY's ROE is +0.94%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, ALNY is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check IMGN's competition here
Abivax S.A. (NASDAQ: ABVX)
ALNY vs ABVX Comparison August 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 32.1B. In comparison, ABVX has a market cap of 8.7B. Regarding current trading prices, ALNY is priced at $240.08 on the NASDAQ, while ABVX trades at $117.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 43.26, whereas ABVX's P/E ratio is -61.82. In terms of profitability, ALNY's ROE is +0.94%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, ALNY is less volatile compared to ABVX. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check ABVX's competition here
ImmunityBio, Inc. (NASDAQ: IBRX)
ALNY vs IBRX Comparison August 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 32.1B. In comparison, IBRX has a market cap of 8.6B. Regarding current trading prices, ALNY is priced at $240.08 on the NASDAQ, while IBRX trades at $8.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 43.26, whereas IBRX's P/E ratio is -8.44. In terms of profitability, ALNY's ROE is +0.94%, compared to IBRX's ROE of +1.35%. Regarding short-term risk, ALNY is less volatile compared to IBRX. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check IBRX's competition here
TG Therapeutics, Inc. (NASDAQ: TGTX)
ALNY vs TGTX Comparison August 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 32.1B. In comparison, TGTX has a market cap of 8.5B. Regarding current trading prices, ALNY is priced at $240.08 on the NASDAQ, while TGTX trades at $55.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 43.26, whereas TGTX's P/E ratio is 20.07. In terms of profitability, ALNY's ROE is +0.94%, compared to TGTX's ROE of +0.72%. Regarding short-term risk, ALNY is less volatile compared to TGTX. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check TGTX's competition here
Blueprint Medicines Corporation (NASDAQ: BPMC)
ALNY vs BPMC Comparison August 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 32.1B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, ALNY is priced at $240.08 on the NASDAQ, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 43.26, whereas BPMC's P/E ratio is -51.58. In terms of profitability, ALNY's ROE is +0.94%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, ALNY is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check BPMC's competition here
Apogee Therapeutics, Inc. (NASDAQ: APGE)
ALNY vs APGE Comparison August 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 32.1B. In comparison, APGE has a market cap of 8.3B. Regarding current trading prices, ALNY is priced at $240.08 on the NASDAQ, while APGE trades at $134.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 43.26, whereas APGE's P/E ratio is -31.14. In terms of profitability, ALNY's ROE is +0.94%, compared to APGE's ROE of -0.30%. Regarding short-term risk, ALNY is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check APGE's competition here
Alkermes plc (NASDAQ: ALKS)
ALNY vs ALKS Comparison August 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 32.1B. In comparison, ALKS has a market cap of 8.3B. Regarding current trading prices, ALNY is priced at $240.08 on the NASDAQ, while ALKS trades at $49.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 43.26, whereas ALKS's P/E ratio is 51.80. In terms of profitability, ALNY's ROE is +0.94%, compared to ALKS's ROE of +0.04%. Regarding short-term risk, ALNY is more volatile compared to ALKS. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check ALKS's competition here
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)
ALNY vs CERE Comparison August 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 32.1B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, ALNY is priced at $240.08 on the NASDAQ, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 43.26, whereas CERE's P/E ratio is -16.47. In terms of profitability, ALNY's ROE is +0.94%, compared to CERE's ROE of -0.72%. Regarding short-term risk, ALNY is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check CERE's competition here
Caris Life Sciences, Inc. (NASDAQ: CAI)
ALNY vs CAI Comparison August 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 32.1B. In comparison, CAI has a market cap of 7.9B. Regarding current trading prices, ALNY is priced at $240.08 on the NASDAQ, while CAI trades at $28.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 43.26, whereas CAI's P/E ratio is 78.70. In terms of profitability, ALNY's ROE is +0.94%, compared to CAI's ROE of +0.19%. Regarding short-term risk, ALNY is less volatile compared to CAI. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check CAI's competition here
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)
ALNY vs RYTM Comparison August 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 32.1B. In comparison, RYTM has a market cap of 7.8B. Regarding current trading prices, ALNY is priced at $240.08 on the NASDAQ, while RYTM trades at $113.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 43.26, whereas RYTM's P/E ratio is -36.45. In terms of profitability, ALNY's ROE is +0.94%, compared to RYTM's ROE of -0.80%. Regarding short-term risk, ALNY is more volatile compared to RYTM. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check RYTM's competition here
Metsera, Inc. (NASDAQ: MTSR)
ALNY vs MTSR Comparison August 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 32.1B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, ALNY is priced at $240.08 on the NASDAQ, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 43.26, whereas MTSR's P/E ratio is -23.58. In terms of profitability, ALNY's ROE is +0.94%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, ALNY is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check MTSR's competition here
Scholar Rock Holding Corporation (NASDAQ: SRRK)
ALNY vs SRRK Comparison August 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 32.1B. In comparison, SRRK has a market cap of 7B. Regarding current trading prices, ALNY is priced at $240.08 on the NASDAQ, while SRRK trades at $58.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 43.26, whereas SRRK's P/E ratio is -16.88. In terms of profitability, ALNY's ROE is +0.94%, compared to SRRK's ROE of -1.60%. Regarding short-term risk, ALNY is less volatile compared to SRRK. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check SRRK's competition here
CG Oncology Inc. (NASDAQ: CGON)
ALNY vs CGON Comparison August 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 32.1B. In comparison, CGON has a market cap of 7B. Regarding current trading prices, ALNY is priced at $240.08 on the NASDAQ, while CGON trades at $78.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 43.26, whereas CGON's P/E ratio is -29.35. In terms of profitability, ALNY's ROE is +0.94%, compared to CGON's ROE of -0.25%. Regarding short-term risk, ALNY is less volatile compared to CGON. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check CGON's competition here
Merus N.V. (NASDAQ: MRUS)
ALNY vs MRUS Comparison August 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 32.1B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, ALNY is priced at $240.08 on the NASDAQ, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 43.26, whereas MRUS's P/E ratio is -17.05. In terms of profitability, ALNY's ROE is +0.94%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, ALNY is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check MRUS's competition here
Arcellx, Inc. (NASDAQ: ACLX)
ALNY vs ACLX Comparison August 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 32.1B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, ALNY is priced at $240.08 on the NASDAQ, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 43.26, whereas ACLX's P/E ratio is -28.27. In terms of profitability, ALNY's ROE is +0.94%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, ALNY is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check ACLX's competition here
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
ALNY vs RETA Comparison August 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 32.1B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, ALNY is priced at $240.08 on the NASDAQ, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 43.26, whereas RETA's P/E ratio is -66.29. In terms of profitability, ALNY's ROE is +0.94%, compared to RETA's ROE of +0.47%. Regarding short-term risk, ALNY is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check RETA's competition here
Belite Bio, Inc (NASDAQ: BLTE)
ALNY vs BLTE Comparison August 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 32.1B. In comparison, BLTE has a market cap of 6.5B. Regarding current trading prices, ALNY is priced at $240.08 on the NASDAQ, while BLTE trades at $161.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 43.26, whereas BLTE's P/E ratio is -86.46. In terms of profitability, ALNY's ROE is +0.94%, compared to BLTE's ROE of -0.21%. Regarding short-term risk, ALNY is less volatile compared to BLTE. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check BLTE's competition here
Cogent Biosciences, Inc. (NASDAQ: COGT)
ALNY vs COGT Comparison August 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 32.1B. In comparison, COGT has a market cap of 6.3B. Regarding current trading prices, ALNY is priced at $240.08 on the NASDAQ, while COGT trades at $36.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 43.26, whereas COGT's P/E ratio is -17.44. In terms of profitability, ALNY's ROE is +0.94%, compared to COGT's ROE of -0.73%. Regarding short-term risk, ALNY is more volatile compared to COGT. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check COGT's competition here
Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
ALNY vs DNTH Comparison August 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 32.1B. In comparison, DNTH has a market cap of 6.3B. Regarding current trading prices, ALNY is priced at $240.08 on the NASDAQ, while DNTH trades at $112.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 43.26, whereas DNTH's P/E ratio is -27.01. In terms of profitability, ALNY's ROE is +0.94%, compared to DNTH's ROE of -0.04%. Regarding short-term risk, ALNY is less volatile compared to DNTH. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check DNTH's competition here
Centessa Pharmaceuticals plc (NASDAQ: CNTA)
ALNY vs CNTA Comparison August 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 32.1B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, ALNY is priced at $240.08 on the NASDAQ, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 43.26, whereas CNTA's P/E ratio is -22.63. In terms of profitability, ALNY's ROE is +0.94%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, ALNY is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check CNTA's competition here
Travere Therapeutics, Inc. (NASDAQ: TVTX)
ALNY vs TVTX Comparison August 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 32.1B. In comparison, TVTX has a market cap of 6.2B. Regarding current trading prices, ALNY is priced at $240.08 on the NASDAQ, while TVTX trades at $67.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 43.26, whereas TVTX's P/E ratio is -148.91. In terms of profitability, ALNY's ROE is +0.94%, compared to TVTX's ROE of -0.56%. Regarding short-term risk, ALNY is less volatile compared to TVTX. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check TVTX's competition here
Erasca, Inc. (NASDAQ: ERAS)
ALNY vs ERAS Comparison August 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 32.1B. In comparison, ERAS has a market cap of 6.2B. Regarding current trading prices, ALNY is priced at $240.08 on the NASDAQ, while ERAS trades at $17.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 43.26, whereas ERAS's P/E ratio is -19.10. In terms of profitability, ALNY's ROE is +0.94%, compared to ERAS's ROE of -0.80%. Regarding short-term risk, ALNY is less volatile compared to ERAS. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check ERAS's competition here
Oruka Therapeutics, Inc. (NASDAQ: ORKA)
ALNY vs ORKA Comparison August 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 32.1B. In comparison, ORKA has a market cap of 6.1B. Regarding current trading prices, ALNY is priced at $240.08 on the NASDAQ, while ORKA trades at $101.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 43.26, whereas ORKA's P/E ratio is -52.48. In terms of profitability, ALNY's ROE is +0.94%, compared to ORKA's ROE of -0.21%. Regarding short-term risk, ALNY is less volatile compared to ORKA. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check ORKA's competition here
PTC Therapeutics, Inc. (NASDAQ: PTCT)
ALNY vs PTCT Comparison August 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 32.1B. In comparison, PTCT has a market cap of 6.1B. Regarding current trading prices, ALNY is priced at $240.08 on the NASDAQ, while PTCT trades at $73.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 43.26, whereas PTCT's P/E ratio is -31.53. In terms of profitability, ALNY's ROE is +0.94%, compared to PTCT's ROE of +0.22%. Regarding short-term risk, ALNY is less volatile compared to PTCT. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check PTCT's competition here
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)
ALNY vs MIRM Comparison August 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 32.1B. In comparison, MIRM has a market cap of 6B. Regarding current trading prices, ALNY is priced at $240.08 on the NASDAQ, while MIRM trades at $98.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 43.26, whereas MIRM's P/E ratio is -6.74. In terms of profitability, ALNY's ROE is +0.94%, compared to MIRM's ROE of -4.10%. Regarding short-term risk, ALNY is less volatile compared to MIRM. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check MIRM's competition here
Definium Therapeutics, Inc. (NASDAQ: DFTX)
ALNY vs DFTX Comparison August 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 32.1B. In comparison, DFTX has a market cap of 5.9B. Regarding current trading prices, ALNY is priced at $240.08 on the NASDAQ, while DFTX trades at $44.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 43.26, whereas DFTX's P/E ratio is N/A. In terms of profitability, ALNY's ROE is +0.94%, compared to DFTX's ROE of -0.85%. Regarding short-term risk, ALNY is less volatile compared to DFTX. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check DFTX's competition here
CRISPR Therapeutics AG (NASDAQ: CRSP)
ALNY vs CRSP Comparison August 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 32.1B. In comparison, CRSP has a market cap of 5.9B. Regarding current trading prices, ALNY is priced at $240.08 on the NASDAQ, while CRSP trades at $60.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 43.26, whereas CRSP's P/E ratio is -12.79. In terms of profitability, ALNY's ROE is +0.94%, compared to CRSP's ROE of -0.24%. Regarding short-term risk, ALNY is less volatile compared to CRSP. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check CRSP's competition here
Xenon Pharmaceuticals Inc. (NASDAQ: XENE)
ALNY vs XENE Comparison August 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 32.1B. In comparison, XENE has a market cap of 5.8B. Regarding current trading prices, ALNY is priced at $240.08 on the NASDAQ, while XENE trades at $60.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 43.26, whereas XENE's P/E ratio is -12.86. In terms of profitability, ALNY's ROE is +0.94%, compared to XENE's ROE of -0.44%. Regarding short-term risk, ALNY is less volatile compared to XENE. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check XENE's competition here
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
ALNY vs LGND Comparison August 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 32.1B. In comparison, LGND has a market cap of 5.6B. Regarding current trading prices, ALNY is priced at $240.08 on the NASDAQ, while LGND trades at $281.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 43.26, whereas LGND's P/E ratio is 30.92. In terms of profitability, ALNY's ROE is +0.94%, compared to LGND's ROE of +0.20%. Regarding short-term risk, ALNY is less volatile compared to LGND. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check LGND's competition here
Cidara Therapeutics, Inc. (NASDAQ: CDTX)
ALNY vs CDTX Comparison August 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 32.1B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, ALNY is priced at $240.08 on the NASDAQ, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 43.26, whereas CDTX's P/E ratio is -19.77. In terms of profitability, ALNY's ROE is +0.94%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, ALNY is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check CDTX's competition here
Abcam plc (NASDAQ: ABCM)
ALNY vs ABCM Comparison August 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 32.1B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, ALNY is priced at $240.08 on the NASDAQ, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 43.26, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, ALNY's ROE is +0.94%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, ALNY is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check ABCM's competition here
IVERIC bio, Inc. (NASDAQ: ISEE)
ALNY vs ISEE Comparison August 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 32.1B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, ALNY is priced at $240.08 on the NASDAQ, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 43.26, whereas ISEE's P/E ratio is -22.44. In terms of profitability, ALNY's ROE is +0.94%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, ALNY is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check ISEE's competition here
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
ALNY vs APLS Comparison August 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 32.1B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, ALNY is priced at $240.08 on the NASDAQ, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 43.26, whereas APLS's P/E ratio is 38.35. In terms of profitability, ALNY's ROE is +0.94%, compared to APLS's ROE of +0.40%. Regarding short-term risk, ALNY is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check APLS's competition here
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD)
ALNY vs ACAD Comparison August 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 32.1B. In comparison, ACAD has a market cap of 5.2B. Regarding current trading prices, ALNY is priced at $240.08 on the NASDAQ, while ACAD trades at $30.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 43.26, whereas ACAD's P/E ratio is 13.77. In terms of profitability, ALNY's ROE is +0.94%, compared to ACAD's ROE of +0.32%. Regarding short-term risk, ALNY is less volatile compared to ACAD. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check ACAD's competition here
Dyne Therapeutics, Inc. (NASDAQ: DYN)
ALNY vs DYN Comparison August 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 32.1B. In comparison, DYN has a market cap of 4.9B. Regarding current trading prices, ALNY is priced at $240.08 on the NASDAQ, while DYN trades at $26.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 43.26, whereas DYN's P/E ratio is -8.18. In terms of profitability, ALNY's ROE is +0.94%, compared to DYN's ROE of -0.64%. Regarding short-term risk, ALNY is less volatile compared to DYN. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check DYN's competition here
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
ALNY vs TERN Comparison August 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 32.1B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, ALNY is priced at $240.08 on the NASDAQ, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 43.26, whereas TERN's P/E ratio is -51.41. In terms of profitability, ALNY's ROE is +0.94%, compared to TERN's ROE of -0.20%. Regarding short-term risk, ALNY is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check TERN's competition here
Edgewise Therapeutics, Inc. (NASDAQ: EWTX)
ALNY vs EWTX Comparison August 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 32.1B. In comparison, EWTX has a market cap of 4.8B. Regarding current trading prices, ALNY is priced at $240.08 on the NASDAQ, while EWTX trades at $44.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 43.26, whereas EWTX's P/E ratio is -23.90. In terms of profitability, ALNY's ROE is +0.94%, compared to EWTX's ROE of -0.39%. Regarding short-term risk, ALNY is less volatile compared to EWTX. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check EWTX's competition here
Parabilis Medicines, Inc. (NASDAQ: PBLS)
ALNY vs PBLS Comparison August 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 32.1B. In comparison, PBLS has a market cap of 4.6B. Regarding current trading prices, ALNY is priced at $240.08 on the NASDAQ, while PBLS trades at $39.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 43.26, whereas PBLS's P/E ratio is -44.58. In terms of profitability, ALNY's ROE is +0.94%, compared to PBLS's ROE of -0.15%. Regarding short-term risk, ALNY is less volatile compared to PBLS. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check PBLS's competition here
Amicus Therapeutics, Inc. (NASDAQ: FOLD)
ALNY vs FOLD Comparison August 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 32.1B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, ALNY is priced at $240.08 on the NASDAQ, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 43.26, whereas FOLD's P/E ratio is -161.00. In terms of profitability, ALNY's ROE is +0.94%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, ALNY is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check FOLD's competition here
Relay Therapeutics, Inc. (NASDAQ: RLAY)
ALNY vs RLAY Comparison August 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 32.1B. In comparison, RLAY has a market cap of 4.5B. Regarding current trading prices, ALNY is priced at $240.08 on the NASDAQ, while RLAY trades at $20.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 43.26, whereas RLAY's P/E ratio is -13.10. In terms of profitability, ALNY's ROE is +0.94%, compared to RLAY's ROE of -0.42%. Regarding short-term risk, ALNY is less volatile compared to RLAY. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check RLAY's competition here
Celcuity Inc. (NASDAQ: CELC)
ALNY vs CELC Comparison August 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 32.1B. In comparison, CELC has a market cap of 4.5B. Regarding current trading prices, ALNY is priced at $240.08 on the NASDAQ, while CELC trades at $92.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 43.26, whereas CELC's P/E ratio is -21.46. In terms of profitability, ALNY's ROE is +0.94%, compared to CELC's ROE of -3.51%. Regarding short-term risk, ALNY is less volatile compared to CELC. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check CELC's competition here
Akero Therapeutics, Inc. (NASDAQ: AKRO)
ALNY vs AKRO Comparison August 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 32.1B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, ALNY is priced at $240.08 on the NASDAQ, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 43.26, whereas AKRO's P/E ratio is -14.57. In terms of profitability, ALNY's ROE is +0.94%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, ALNY is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check AKRO's competition here
Alpine Immune Sciences, Inc. (NASDAQ: ALPN)
ALNY vs ALPN Comparison August 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 32.1B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, ALNY is priced at $240.08 on the NASDAQ, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 43.26, whereas ALPN's P/E ratio is -101.52. In terms of profitability, ALNY's ROE is +0.94%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, ALNY is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check ALPN's competition here
Enliven Therapeutics, Inc. (NASDAQ: ELVN)
ALNY vs ELVN Comparison August 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 32.1B. In comparison, ELVN has a market cap of 4.4B. Regarding current trading prices, ALNY is priced at $240.08 on the NASDAQ, while ELVN trades at $61.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 43.26, whereas ELVN's P/E ratio is -36.53. In terms of profitability, ALNY's ROE is +0.94%, compared to ELVN's ROE of -0.19%. Regarding short-term risk, ALNY is less volatile compared to ELVN. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check ELVN's competition here
Veradermics, Incorporated (NYSE: MANE)
ALNY vs MANE Comparison August 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 32.1B. In comparison, MANE has a market cap of 4.3B. Regarding current trading prices, ALNY is priced at $240.08 on the NASDAQ, while MANE trades at $102.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 43.26, whereas MANE's P/E ratio is -32.54. In terms of profitability, ALNY's ROE is +0.94%, compared to MANE's ROE of -0.29%. Regarding short-term risk, ALNY is less volatile compared to MANE. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check MANE's competition here
Opthea Limited (NASDAQ: OPT)
ALNY vs OPT Comparison August 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 32.1B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, ALNY is priced at $240.08 on the NASDAQ, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 43.26, whereas OPT's P/E ratio is -1.52. In terms of profitability, ALNY's ROE is +0.94%, compared to OPT's ROE of +1.18%. Regarding short-term risk, ALNY is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check OPT's competition here
PureTech Health plc (NASDAQ: PRTC)
ALNY vs PRTC Comparison August 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 32.1B. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, ALNY is priced at $240.08 on the NASDAQ, while PRTC trades at $17.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 43.26, whereas PRTC's P/E ratio is -3.78. In terms of profitability, ALNY's ROE is +0.94%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, ALNY is less volatile compared to PRTC. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check PRTC's competition here
Adaptive Biotechnologies Corporation (NASDAQ: ADPT)
ALNY vs ADPT Comparison August 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 32.1B. In comparison, ADPT has a market cap of 4.2B. Regarding current trading prices, ALNY is priced at $240.08 on the NASDAQ, while ADPT trades at $26.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 43.26, whereas ADPT's P/E ratio is -64.02. In terms of profitability, ALNY's ROE is +0.94%, compared to ADPT's ROE of -0.33%. Regarding short-term risk, ALNY is less volatile compared to ADPT. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check ADPT's competition here
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX)
ALNY vs AMLX Comparison August 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 32.1B. In comparison, AMLX has a market cap of 4.2B. Regarding current trading prices, ALNY is priced at $240.08 on the NASDAQ, while AMLX trades at $37.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 43.26, whereas AMLX's P/E ratio is -24.97. In terms of profitability, ALNY's ROE is +0.94%, compared to AMLX's ROE of -0.53%. Regarding short-term risk, ALNY is less volatile compared to AMLX. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check AMLX's competition here
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
ALNY vs MRTX Comparison August 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 32.1B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, ALNY is priced at $240.08 on the NASDAQ, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 43.26, whereas MRTX's P/E ratio is -4.82. In terms of profitability, ALNY's ROE is +0.94%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, ALNY is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check MRTX's competition here
IDEAYA Biosciences, Inc. (NASDAQ: IDYA)
ALNY vs IDYA Comparison August 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 32.1B. In comparison, IDYA has a market cap of 4B. Regarding current trading prices, ALNY is priced at $240.08 on the NASDAQ, while IDYA trades at $42.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 43.26, whereas IDYA's P/E ratio is -21.90. In terms of profitability, ALNY's ROE is +0.94%, compared to IDYA's ROE of -0.16%. Regarding short-term risk, ALNY is less volatile compared to IDYA. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check IDYA's competition here
Tango Therapeutics, Inc. (NASDAQ: TNGX)
ALNY vs TNGX Comparison August 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 32.1B. In comparison, TNGX has a market cap of 4B. Regarding current trading prices, ALNY is priced at $240.08 on the NASDAQ, while TNGX trades at $24.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 43.26, whereas TNGX's P/E ratio is -29.84. In terms of profitability, ALNY's ROE is +0.94%, compared to TNGX's ROE of -0.26%. Regarding short-term risk, ALNY is less volatile compared to TNGX. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check TNGX's competition here
Viking Therapeutics, Inc. (NASDAQ: VKTX)
ALNY vs VKTX Comparison August 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 32.1B. In comparison, VKTX has a market cap of 4B. Regarding current trading prices, ALNY is priced at $240.08 on the NASDAQ, while VKTX trades at $34.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 43.26, whereas VKTX's P/E ratio is -7.33. In terms of profitability, ALNY's ROE is +0.94%, compared to VKTX's ROE of -0.95%. Regarding short-term risk, ALNY is less volatile compared to VKTX. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check VKTX's competition here
Arcus Biosciences, Inc. (NYSE: RCUS)
ALNY vs RCUS Comparison August 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 32.1B. In comparison, RCUS has a market cap of 4B. Regarding current trading prices, ALNY is priced at $240.08 on the NASDAQ, while RCUS trades at $31.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 43.26, whereas RCUS's P/E ratio is -8.09. In terms of profitability, ALNY's ROE is +0.94%, compared to RCUS's ROE of -0.88%. Regarding short-term risk, ALNY is less volatile compared to RCUS. This indicates lower risk in terms of short-term price fluctuations for ALNY.Check RCUS's competition here
Telix Pharmaceuticals Limited (NASDAQ: TLX)
ALNY vs TLX Comparison August 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 32.1B. In comparison, TLX has a market cap of 4B. Regarding current trading prices, ALNY is priced at $240.08 on the NASDAQ, while TLX trades at $11.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 43.26, whereas TLX's P/E ratio is 122.03. In terms of profitability, ALNY's ROE is +0.94%, compared to TLX's ROE of +0.07%. Regarding short-term risk, ALNY is more volatile compared to TLX. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check TLX's competition here
Denali Therapeutics Inc. (NASDAQ: DNLI)
ALNY vs DNLI Comparison August 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALNY stands at 32.1B. In comparison, DNLI has a market cap of 4B. Regarding current trading prices, ALNY is priced at $240.08 on the NASDAQ, while DNLI trades at $24.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALNY currently has a P/E ratio of 43.26, whereas DNLI's P/E ratio is -8.66. In terms of profitability, ALNY's ROE is +0.94%, compared to DNLI's ROE of -0.55%. Regarding short-term risk, ALNY is more volatile compared to DNLI. This indicates higher risk in terms of short-term price fluctuations for ALNY.Check DNLI's competition here